Abstract
Out of the 15 discrete proteins encoding the total amount of genetic information in the chromosomes of human immunodeficiency virus type 1; three perform the vital enzymatic functions i.e. a reverse transcription, an integration, and proteolysis. The HIV integrase is the new validated drug target against AIDS amongst all essential enzymes due to the lack of the human homologue. In last few years quite, a few but potent inhibitors inhibiting HIV-1 integrase have been recognized and hence have gained a state-of-the-art for treating the infection caused by HIV-1. The greater understanding of HIV-integrase biological structure has further lead to continuous efforts for the proposal of novel inhibitors targeting diverse steps in the progression of integration with the primary goal to overcome resistance due to the rapid occurrence of integrase mutations in the treated patients. This review is focused on various aspects of the recently approved HIVintegrase inhibitor “dolutegravir”, its efficacy, safety profiles with the clinical data and molecular modeling studies highlighting its importance over the already approved HIV-integrase inhibitors.
Keywords: AIDS, HIV, integrase, dolutegravir, reteroviral, homologue.
Current HIV Research
Title:A Novel Integrase Targeting Agent to Explore the Future Prospective of HIV Eradication: Dolutegravir
Volume: 12 Issue: 5
Author(s): Bawneet K. Narang, Gurpreet K. Grewal, Subhajit Roy, Jitender Bariwal, Manish K. Gupta and Ravindra K. Rawal
Affiliation:
Keywords: AIDS, HIV, integrase, dolutegravir, reteroviral, homologue.
Abstract: Out of the 15 discrete proteins encoding the total amount of genetic information in the chromosomes of human immunodeficiency virus type 1; three perform the vital enzymatic functions i.e. a reverse transcription, an integration, and proteolysis. The HIV integrase is the new validated drug target against AIDS amongst all essential enzymes due to the lack of the human homologue. In last few years quite, a few but potent inhibitors inhibiting HIV-1 integrase have been recognized and hence have gained a state-of-the-art for treating the infection caused by HIV-1. The greater understanding of HIV-integrase biological structure has further lead to continuous efforts for the proposal of novel inhibitors targeting diverse steps in the progression of integration with the primary goal to overcome resistance due to the rapid occurrence of integrase mutations in the treated patients. This review is focused on various aspects of the recently approved HIVintegrase inhibitor “dolutegravir”, its efficacy, safety profiles with the clinical data and molecular modeling studies highlighting its importance over the already approved HIV-integrase inhibitors.
Export Options
About this article
Cite this article as:
Narang K. Bawneet, Grewal K. Gurpreet, Roy Subhajit, Bariwal Jitender, Gupta K. Manish and Rawal K. Ravindra, A Novel Integrase Targeting Agent to Explore the Future Prospective of HIV Eradication: Dolutegravir, Current HIV Research 2014; 12 (5) . https://dx.doi.org/10.2174/1570162X12666140807150753
DOI https://dx.doi.org/10.2174/1570162X12666140807150753 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic:Novel Targets in Cancer Therapy(Guest Editor: Debabrata Banerjee)]
Current Pharmaceutical Biotechnology Cerebral Hemorrhage Produced by Thrombolytic and Anti-Thrombotic Agents: A Review
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Synaptic Inputs of Neural Afferent Pathways to Vasopressin- and Oxytocin-Secreting Neurons of Supraoptic and Paraventricular Hypothalamic Nuclei
Endocrine, Metabolic & Immune Disorders - Drug Targets Preface [Hot Topic: Peripheral Arterial Disease (Guest Editors: G. Brevetti / M. Chiariello)]
Current Drug Targets - Cardiovascular & Hematological Disorders Dietary Intakes and Food Habits of Wheelchair Basketball Athletes Compared to Gym Attendees and Individuals who do not Practice Sport Activity
Endocrine, Metabolic & Immune Disorders - Drug Targets Stem Cell Therapy for Neurologic Disorders: Therapeutic Potential of Adipose-Derived Stem Cells
Current Drug Targets Insulin Resistance-Induced Hypertension and a Role of Perivascular CGRPergic Nerves
Current Protein & Peptide Science Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
Current Drug Targets Adenosine-to-Inosine RNA Editing: Perspectives and Predictions
Mini-Reviews in Medicinal Chemistry Metabolism of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy: A Review of the Literature
Current Drug Metabolism Coronary Artery Ectasia-A Review of Current Literature
Current Cardiology Reviews Differential Impact of Biologic Therapy on Heart Function Biomarkers in Rheumatoid Arthritis Patients: Observational Study on Etanercept, Adalimumab, and Tocilizumab
Current Pharmaceutical Design Nitric Oxide and its Antithrombotic Action in the Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders Gastrointestinal Sparing Anti-Inflammatory Drugs - Effects on Ulcerogenic and Healing Responses
Current Pharmaceutical Design Involvement of Nucleotide Excision and Mismatch Repair Mechanisms in Double Strand Break Repair
Current Genomics Multi-Objective Optimization Methods in De Novo Drug Design
Mini-Reviews in Medicinal Chemistry Elucidating the Pivotal Role of Immune Players in the Management of COVID-19: Focus on Mesenchymal Stem Cells and Inflammation
Current Stem Cell Research & Therapy Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Current Pharmaceutical Design Interaction of Autophagy and Toll-Like Receptors: A Regulatory Cross- Talk - Even in Cancer Cells?
Current Drug Targets Persistent Allergic Minimum Phlogosis as Mechanistic Link Between Recurrent Respiratory Infections and Atopy: A Single Center Pilot Study
Current Respiratory Medicine Reviews